Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. (Q53339552)

13 May 2018

title

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. (English)

1 reference

13 May 2018

0 references

7

Soininen H

1 reference

13 May 2018

Tapiola T

1

1 reference

13 May 2018

Pirttilä T

2

1 reference

13 May 2018

Mikkonen M

3

1 reference

13 May 2018

Mehta PD

4

1 reference

13 May 2018

Alafuzoff I

5

1 reference

13 May 2018

Koivisto K

6

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 February 2000

1 reference

13 May 2018

published in

Neuroscience Letters

1 reference

13 May 2018

volume

280

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

119-122

1 reference

13 May 2018

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Increased plasma amyloid beta protein 1-42 levels in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900767-9

7 January 2021

10.1016/S0304-3940(00)00767-9

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018